A much lower (4/32; 12.5%) prevalence of NRAS mutations was instead observed; again, no difference in mutation frequency distribution among cells lines from primary (1/8; 12.5%) versus metastatic (3/24; 12.5%) melanomas was registered. The gene discussed is NRAS; the disease is melanoma.